Veru Completes Enrollment in Phase 2b Obesity Trial, Data Readouts Set for 2027
VERU is trading near its 52-week low of $2.05 (14% above the low) on light trading volume (0.1× avg).
Summary
Veru has fully enrolled its Phase 2b PLATEAU trial testing enobosarm with semaglutide in older obese patients, exceeding the 200-patient target. This marks a key operational milestone for the company's lead obesity program. Interim analysis results are now expected in Q1 2027, with final topline data in Q4 2027. The trial builds on the positive Phase 2b QUALITY study and the June 2026 clinical supply agreement with Novo Nordisk for Wegovy. With a market cap of only $36 million, positive data could significantly de-risk the asset and attract partnership interest, though the company remains under financial pressure with a going concern warning and an active ATM offering.
At the time of this announcement, VERU was trading at $2.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.1M. The 52-week trading range was $2.05 to $7.33. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.